Skip to main content

home

OVERVIEW
Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China.

With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.

OUR STRATEGY
Enabling value creation by investing in Chinese subsidiaries of foreign companies active in the biomedical outside China
GIBF partners with selected companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders.
PORTFOLIO
Companies' Overview
Partnering with top-tier international life sciences companies offering innovative solutions to Chinese healthcare needs.

COMPANY

InMode (NASDAQ: INMD) (Exit)

SECTOR

Medical Device

COMPANY

G-Medical (NASDAQ: GMVD)

SECTOR

Medical Device

COMPANY

CarboFix

SECTOR

Medical Device
OUR PEOPLE
Meet Our Management
Where global leaders in life sciences meet local talents to achieve cross-border investments and companies' formation.
DR. YEHOSHUA(SHUKI) GLEITMAN
Founding Partner and Chairman
PROF. SHLOMO NOY
Founding Partner and Chief Medical Officer
AVNER LUSHI
Founding Partner and CEO
CARL GENG
Founding Partner and General Manager
Latest
News

VIEW ALL

Latest
News
shuki-外交特别贡献奖

Dr. Shuki Gleitman receives Certificates of Appreciation from Israeli Foreign Affairs

(25 Dec, 2023) Israeli Foreign Affairs Minister Mr. Eli Cohen awarded certificates of appreciation to businessmen and organizations for their contribution to Israel's foreign relations and strengthening its global position.

投资组合向右箭头
visionix news

New partnership between 20/20NOW and Visionix Americas

(16 Nov, 2023) Visionix USA is proud to share they recently entered a strategic alliance with 20/20NOW to help bring cost effective, in-office, quality synchronous tele-optometry comprehensive eye exams and ocular telemedicine closer to more patients throughout the United States.

投资组合向右箭头
silexion

Silexion Therapeutics Presented The LODER™ Phase 2 Summary Results In The 2023 ESMO Immuno-Oncology Congress

(30 Oct, 2023) Results from a multinational Phase 2 clinical study (Protact Trial) of siRNA directed against the oncogenic KRAS G12D and G12V mutations  in an extended release formulation (Loder™) was presented at the 2023 European Society for Medical Oncology (ESMO) annual congress (Abstract 1626P). 

投资组合向右箭头